Table of Contents Author Guidelines Submit a Manuscript
Behavioural Neurology
Volume 17, Issue 1, Pages 43-51

Neuropharmacological Treatment of Mental Dysfunction in Parkinson’s Disease

Patrick McNamara and Raymon Durso

Department of Neurology, Boston University School of Medicine, Boston VA Healthcare System, Boston, MA, USA

Received 26 April 2006; Accepted 26 April 2006

Copyright © 2006 Hindawi Publishing Corporation and the authors. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Many patients with Parkinson's Disease (PD) experience significant cognitive and mood impairment -even early in the course of the disease. These mental impairments are only partially responsive to levodopa treatment and are often as disabling as the motor impairment, particularly in mid and late stages of the disease. Investigators have recently begun a search for new agents that can effectively treat mental dysfunction of PD. Although there have been only a handful of properly controlled clinical trials of interventions targeted at amelioration of mental dysfunction in PD, progress has been made. Based on the available evidence, targeting catecholaminergic and cholinergic function may be an effective strategy for amelioration of cognitve, mood and psychiatric disturbances in PD.